Methylation of cytosines located 5′ to guanosine is known to have a profound effect on the expression of several eukaryotic genes (Bird, 1992). In normal cells, methylation occurs predominantly in CG-poor regions, while CG-rich areas, called CpG islands, remain unmethylated. Aberrant methylation of normally unmethylated CpG islands has been documented as a relatively frequent event […]

Aberrant methylation of the p15 promoter region has been shown to cause inactivation in several gliomas and leukemias. The CpG WIZ® p15 Amplification Kit is used for determining the methylation status of the p15 promoter by methylation-specific PCR (MSP). The kit contains primers targeted to regions of the p15 promoter where the sequences are most […]

A differentially methylated site exists in the CpG islands of SNRPN (small nuclear ribonucleoprotein-associated polypeptide N), a candidate gene for Prader-Willi/Angelman Syndrome. Normally, this site is methylated and inactive on the maternal homolog and unmethylated and transcriptionally active on the paternal homolog. In research samples from Prader-Willi individuals, only the methylated allele is present, while […]

Expression of p16*, a tumor suppressor gene, is repressed in a variety of cancers such as bladder, colon and retinoblastoma. Methylation of CpG islands in the p16 promoter has been shown to be responsible for inactivation of this gene in certain cases. The CpG WIZ® p16 Amplification Kit is used for determining the methylation status […]

Methylation of cytosines located 5′ to guanosine is known to have a profound effect on the expression of several eukaryotic genes (Bird, 1992). In normal cells, methylation occurs predominantly in CG-poor regions, while CG-rich areas, called CpG islands, remain unmethylated. Aberrant methylation of normally unmethylated CpG islands has been documented as a relatively frequent event […]